SIU 2018

SIU 2018: Advances in Renal Imaging for Tumor Tissue Characterization

Seoul, South-Korea (UroToday.com) Dr. Gaitonde provided a brief update to advances in renal imaging for tumor tissue characterization.  Renal masses are often incidentally found nowadays, often on non-contrast imaging done for other reasons. As such, we are seeing a lot of patients with renal masses – many of whom may not require treatment. ~25-30% of masses < 4 cm are benign – but at this time, we don’t have reliable imaging modalities to identify patients who can avoid treatment.
 

SIU 2018: Multiparametric Ultrasound in Diagnosis of Prostate Cancer

Seoul, South-Korea (UroToday.com) Dr. Rukstalis gave a great talk about the role of “multiparametric” ultrasound in the diagnosis (and eventually treatment?) of prostate cancer – his terminology of multiparametic is slightly tongue-in-cheek, to take over the terminology from the MRI world. The basis for this talk is the concept that the future is merging diagnostics with therapeutics. Eventually, it will be hard to separate these two into distinct steps – and so, those who the diagnostics will do the therapeutics. If urologists are not careful, this can transition completely to radiology – in order to counteract this, we need to be on the forefront of the imaging diagnostics as well!

SIU 2018: Biomarkers Are Cost Effective and Useful in Patient Selection

Seoul, South-Korea (UroToday.com) Derya Tilki, MD gave an overview of the role and cost-effectiveness of biomarkers in prostate cancer. In this presentation, she reviewed diagnostic biomarkers in the pre-biopsy setting, presented their use in the initial or repeat biopsy setting, and provided a brief overview of their cost-effectiveness.

SIU 2018: State of the Art Lecture: Nephron Sparing Surgery in the Patient Over 75 Years of Age

Seoul, South-Korea (UroToday.com) Dr. Mulders discussed the controversial topic of performing nephron sparing surgery in patients older than 75. Renal cell carcinoma (RCC) is the most common renal cancer, representing 80-85% of renal cancers. Approximately 2-3% of all malignancies are RCC, and it is the 10th most common cancer in men and women with a continuing rise in incidence in recent years. The mean age is 64 with a peak rate increase of kidney cancer cases at the ages of 85-89. It is more common in North Europe and America. 

SIU 2018: PET and Fluorescence Imaging for Recurrent/Advanced Prostate Cancer

Seoul, South-Korea (UroToday.com) PET imaging has become a staple of recurrent and advanced prostate cancer, with technology rapidly progressing – and evidence having difficulty keeping up. In this talk, Dr. Miki briefly reviews PET imaging and fluorescence technology. He went through a lot of data very quickly, but below, I highlight the take-away points from his talk. As we all know, the current standards for prostate imaging and staging (CT Abdomen/Pelvis and NM Bone scan) have very low sensitivities (especially at low PSA levels) and therefore may not detect disease until it is very advanced. PET/CT (combination with CT scans) have begun to fill in that need and bridge the gap. 

SIU 2018: MRI Should Be Performed in All Patients Prior to Biopsy

Seoul, South-Korea (UroToday.com) Dr. Jun Hyuk Hong gave his point of view on the role of multiparametric MRI (mpMRI) in the diagnosis of prostate cancer. The ideal goals of a prostate biopsy are to detect clinically significant cancer, to reduce under-diagnosis, and to avoid unnecessary biopsies and over diagnosis of indolent disease. It is known that the risk of prostate cancer, and specifically of clinically significant cancer, is strongly correlated to PSA levels. 1 However, PSA on its own is not enough.

SIU 2018: Robotic Assisted Radical Cystectomy: Present and Future

Seoul, South-Korea (UroToday.com) An encompassing overview of robotic radical cystectomy was given in this talk, by Dr. Rodriguez. Radical cystectomy remains the standard of care for muscle invasive bladder cancer and some types of non-muscle invasive bladder cancer. However, it is a procedure that still has significant morbidity, with transfusion required in 40% of the patients, complications endured by 31% of the patients, and readmission rates as high as 21%.1
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe